AstraZeneca


INSURERS EXUDE CONFIDENCE. RIGHTLY SO

21/09/23 -"Insurers have been on a roll of late (see next chart) so that the ytd performance is a very respectable 16% gain, or 5% more than the Stoxx600 index. This is not bad for a sector weighting of €520bn. ..."

Pages
73
Language
English
Published on
21/09/23
You may also be interested by these reports :
07/05/25
Q1 profits exceeded the street’s expectations. Nonetheless, 2025 guidance was downgraded owing to competition from compounded drugs, which, however, ...

06/05/25
1:10 share split adjustments – Downgrade to Add (prev.: Buy)

06/05/25
Q1 results met expectations, and strong growth was witnessed across the segments as well as three key molecules. Of note was a rebound in the animal ...

05/05/25
BioNTech’s narrative is straightforward: the company develops drugs for life-threatening illnesses and generated significant revenue by developing ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO